Alzinova AB is a Swedish biotechnology enterprise engaged in drug discovery research for Alzheimer’s disease. The company's proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.Read more »
Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy. The unique properties of the AβCC peptide™ technology has also enabled the development of a monoclonal antibody with 100% specificity for the synapse-damaging oligomers. It is currently under validation as a diagnostic tool.
Alzinova AB and Clinical Research Services Turku Oy (CRST) have initiated a cooperation to prepare… Read more »
Alzinova has completed a second pharmacological study of the vaccine ALZ-101 in an animal model.… Read more »
Alzinova’s vaccine ALZ-101, has successfully been evaluated in a novel species and via a novel… Read more »